Kairos Pharma to Present at H.C. Wainwright Global Investment Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is scheduled for September 8–10, 2025, at the Lotte New York Palace Hotel in New York. This presentation provides an opportunity for the company to showcase its progress and strategic direction to potential investors and industry stakeholders.

The company's lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy often results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. This approach addresses a significant unmet medical need in oncology, where drug resistance remains a major challenge in cancer treatment.

Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials represent critical milestones in the development of potential new treatment options for patients with limited alternatives. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA. InvestorWire, a specialized communications platform, provides advanced wire-grade press release syndication services and is one of 70+ brands within the Dynamic Brand Portfolio @IBN that delivers comprehensive corporate communications solutions. For more information, visit https://www.InvestorWire.com.